Sham Innovation Santé is set to exit the oncology diagnostics test developer in an cash-and-stock acquisition expected to close later this year.
Molecular diagnostics technology producer Veracyte has agreed to buy HalioDx, a France-based cancer diagnostics technology developer backed by health insurance provider Sham, for appproximately €260m ($318m).
The deal, which is comprised of about $180m in cash and up to $138m in stock, is expected to close in the third quarter of this year.
Founded in 2014, HalioDx is developing diagnostics tests used by oncologists to support the care of cancer patients. It also supplies its products and services to drug…
